{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:02:34Z","timestamp":1792512154844,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ghir.2024.101608","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T09:36:48Z","timestamp":1722591408000},"page":"101608","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Medical treatment of acromegaly \u2013 When the tumor size matters: A narrative review"],"prefix":"10.1016","volume":"78","author":[{"given":"Mirjana","family":"Doknic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Stojanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Miljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihajlo","family":"Milicevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ghir.2024.101608_bb0005","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.ghir.2024.101608_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","article-title":"Consensus on criteria for acromegaly diagnosis and remission","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0020","doi-asserted-by":"crossref","first-page":"668","DOI":"10.4158\/EP14575.DSCR","article-title":"American association of clinical endocrinologists and American college of endocrinology disease state clinical review: management of acromegaly patients: what is the role of pre-operative medical therapy?","volume":"21","author":"Fleseriu","year":"2015","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.ghir.2024.101608_bb0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.21037\/atm-22-414","article-title":"Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study","volume":"10","author":"Zhao","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.ghir.2024.101608_bb0030","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11102-014-0570-0","article-title":"Mercado M octreotide LAR treatment of acromegaly in \u201creal life\u201d: long-term outcome at a tertiary care center","volume":"18","author":"Espinosa-de-los-Monteros","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0035","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0040","series-title":"Long-Term Safety and Efficacy of Long-Acting Pasireotide in Acromegaly Endocrine","first-page":"396","volume":"74","author":"Akirov","year":"2021"},{"key":"10.1016\/j.ghir.2024.101608_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000381644","article-title":"Pegvisomant treatment in acromegaly","volume":"103","author":"Neggers","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ghir.2024.101608_bb0050","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"PRIMARYS Investigators tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ghir.2024.101608_bb0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.yfrne.2013.07.005","article-title":"Somatostatin receptors: from signaling to clinical practice","volume":"34","author":"Theodoropoulou","year":"2013","journal-title":"Front. Neuroendocrinol."},{"issue":"3","key":"10.1016\/j.ghir.2024.101608_bb0065","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1210\/jc.2004-1093","article-title":"Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly","volume":"90","author":"Bevan","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1\u20132","key":"10.1016\/j.ghir.2024.101608_bb0070","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.mce.2008.02.002","article-title":"Antitumor effects of somatostatin","volume":"286","author":"Pyronnet","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0075","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11102-015-0677-y","article-title":"The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0080","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41467-023-36673-z","article-title":"Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine","volume":"14","author":"Zhao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ghir.2024.101608_bb0085","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-15-0391","article-title":"Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly","volume":"174","author":"Gatto","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0090","doi-asserted-by":"crossref","first-page":"801","DOI":"10.7150\/ijbs.86736","article-title":"Connexin 36 mediated intercellular endoplasmic reticulum stress transmission induces SSTA resistance in growth hormone pituitary adenoma","volume":"20","author":"Wang","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"13","key":"10.1016\/j.ghir.2024.101608_bb0095","article-title":"Surgical outcome and evaluation of strategies in the management of growth hormone-secreting pituitary adenomas after initial transsphenoidal pituitary adenectomy failure","volume":"14","author":"Yan","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ghir.2024.101608_bb0100","first-page":"2779","article-title":"Lombardi G long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly","volume":"86","author":"Colao","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/eje.1.01968","article-title":"Predictors and rates of treatment-resistant tumor growth in acromegaly","volume":"153","author":"Besser","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0110","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac114","article-title":"Preoperative medical treatment for patients with acromegaly: yes or no?","volume":"6","author":"Albarel","year":"2022","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.ghir.2024.101608_bb0115","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0026-0495(96)90088-8","article-title":"Presurgical octreotide: treatment in acromegaly","volume":"45","author":"Stevenaert","year":"1996","journal-title":"Metabolism"},{"key":"10.1016\/j.ghir.2024.101608_bb0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/eje.0.1450137","article-title":"Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical Centre","volume":"145","author":"Abe","year":"2001","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0125","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1210\/jc.2008-0315","article-title":"Preoperative octreotide treatment of acromegaly study group. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial","volume":"93","author":"Carlsen","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ghir.2024.101608_bb0130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1530\/EC-20-0414","article-title":"Rodr\u00edguez Berrocal V Presurgical somatostatin receptor ligand treatment does not affect tumor consistency in GH-secreting pituitary macroadenomas","volume":"10","author":"Araujo-Castro","year":"2021","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.ghir.2024.101608_bb0135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clineuro.2018.02.006","article-title":"Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: a long-term single-center experience","volume":"167","author":"Lv","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ghir.2024.101608_bb0140","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1530\/EJE-09-0908","article-title":"Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial","volume":"162","author":"Mao","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2020.101354","article-title":"Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: a hospital-based study of 237 cases","volume":"55","author":"Shen","year":"2020","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ghir.2024.101608_bb0150","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","article-title":"Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly","volume":"71","author":"Colao","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0155","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1365-2265.2011.03982.x","article-title":"POTA study group six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure","volume":"74","author":"Carlsen","year":"2011","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"10.1016\/j.ghir.2024.101608_bb0160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11102-009-0169-z","article-title":"Effects of lanreotide SR and autogel on tumor mass in patients with acromegaly: a systematic review","volume":"13","author":"Mazziotti","year":"2010","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0165","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1365-2265.2005.02317.x","article-title":"Bronstein MD treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution","volume":"63","author":"Jallad","year":"2005","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2265.2006.02467.x","article-title":"First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial","volume":"64","author":"Colao","year":"2006","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0175","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1210\/jc.2005-2110","article-title":"Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients","volume":"91","author":"Colao","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0180","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","article-title":"Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage","volume":"91","author":"Cozzi","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0185","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","article-title":"A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly","volume":"66","author":"Mercado","year":"2007","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0190","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1530\/EJE-07-0383","article-title":"Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly","volume":"157","author":"Colao","year":"2007","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0195","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1210\/jc.2008-0424","article-title":"Growth hormone-secreting tumor shrinkage after 3 months of octreotide-LAR therapy predicts the response at 12 months","volume":"93","author":"Colao","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0200","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4158\/EP.14.7.846","article-title":"Effects of lanreotide autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study","volume":"14","author":"Attanasio","year":"2008","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.ghir.2024.101608_bb0205","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2009-0941","article-title":"Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study","volume":"94","author":"Colao","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","article-title":"Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly","volume":"71","author":"Colao","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0215","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ghir.2024.101608_bb0220","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1210\/jc.2012-3072","article-title":"A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy","volume":"98","author":"Annamalai","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.ghir.2024.101608_bb0225","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","article-title":"Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter","volume":"18","author":"Sheppard","year":"2015","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12902-016-0096-8","article-title":"Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, phase III study","volume":"16","author":"Bronstein","year":"2016","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.ghir.2024.101608_bb0235","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.21037\/gs.2019.06.04","article-title":"Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas","volume":"8","author":"Tortora","year":"2019","journal-title":"Gland Surg."},{"key":"10.1016\/j.ghir.2024.101608_bb0240","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1530\/EJE-19-0681","article-title":"Is MRI follow-up relevant in patients with GH-secreting pituitary adenomas primarily treated and responsive to long-acting somatostatin analogues (SMSa)?","volume":"182","author":"Grandgeorge","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0245","doi-asserted-by":"crossref","first-page":"285","DOI":"10.5603\/EP.a2020.0050","article-title":"Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin LAR) in patients with acromegaly","volume":"71","author":"Bolanowski","year":"2020","journal-title":"Endokrynol. Pol."},{"issue":"2","key":"10.1016\/j.ghir.2024.101608_bb0250","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","article-title":"PRIMARYS study group predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0255","first-page":"425","article-title":"The therapeutic response of somatotropinomas according to the T2-weighted signal intensity on the MRI","volume":"94","author":"Sc\u00e2nteie","year":"2021","journal-title":"Med. Pharm. Rep."},{"key":"10.1016\/j.ghir.2024.101608_bb0260","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3171\/2014.10.JNS14496","article-title":"Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly","volume":"122","author":"Schwyzer","year":"2015","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ghir.2024.101608_bb0265","article-title":"Personalized medicine in acromegaly: The ACROFAST study","volume":"29","author":"Marques-Pamies","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0270","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1055\/s-0043-107245","article-title":"Stratakis CA 3D volumetric measurements of GH secreting adenomas correlate with baseline pituitary function, initial surgery success rate, and disease control","volume":"49","author":"Tirosh","year":"2017","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ghir.2024.101608_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2020.101342","article-title":"A single-center observational study assessing the predictive factors associated with the prognosis of acromegaly","volume":"55","author":"Diri","year":"2020","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ghir.2024.101608_bb0280","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.677919","article-title":"Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective","volume":"12","author":"Nista","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ghir.2024.101608_bb0285","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s11102-017-0788-8","article-title":"T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective","volume":"20","author":"Potorac","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0290","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11102-018-0877-3","article-title":"Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas","volume":"21","author":"Dogansen","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0295","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1210\/jc.2003-030110","article-title":"Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?","volume":"88","author":"Cozzi","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0300","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1012832230598","article-title":"Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly","volume":"3","author":"Cozzi","year":"2000","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0305","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3171\/2023.7.JNS23858","article-title":"Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly","volume":"140","author":"Zhang","year":"2023","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ghir.2024.101608_bb0310","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/cen.14465","article-title":"Preoperative prediction of granulation pattern subtypes in GH-secreting pituitary adenomas","volume":"95","author":"Heng","year":"2021","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0315","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ghir.2024.101608_bb0320","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ecl.2014.10.002","article-title":"Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene","volume":"44","author":"Daly","year":"2015","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.ghir.2024.101608_bb0325","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0330","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1210\/jc.2018-01979","article-title":"How to position Pasireotide LAR treatment in acromegaly","volume":"104","author":"Coopmans","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0335","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S2213-8587(19)30113-5","article-title":"Potential antitumour activity of pasireotide on pituitary tumours in acromegaly","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0340","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S2213-8587(19)30186-X","article-title":"Shrinkage of pituitary adenomas with pasireotide - Authors\u2019 reply","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0345","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.935759","article-title":"Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis","volume":"13","author":"Mondin","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ghir.2024.101608_bb0355","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-20-0767","article-title":"Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response","volume":"184","author":"Chiloiro","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0360","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0365","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1530\/EC-19-0332","article-title":"Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study","volume":"8","author":"Lasolle","year":"2019","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.ghir.2024.101608_bb0370","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0155","article-title":"Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly","volume":"12","author":"Marques","year":"2023","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.ghir.2024.101608_bb0375","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s12020-019-01874-4","article-title":"Acromegaly can be cured by first-line pasireotide treatment?","volume":"64","author":"Chiloiro","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.ghir.2024.101608_bb0380","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1507\/endocrj.EJ17-0487","article-title":"Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly","volume":"65","author":"Yamamoto","year":"2018","journal-title":"Endocr. J."},{"key":"10.1016\/j.ghir.2024.101608_bb0385","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/EC-19-0004","article-title":"AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients","volume":"8","author":"Daly","year":"2019","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.ghir.2024.101608_bb0390","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0395","doi-asserted-by":"crossref","first-page":"e1571","DOI":"10.1210\/clinem\/dgad378","article-title":"Long-term efficacy and safety of Pasireotide in patients with acromegaly: 14 years of single-center real-world experience","volume":"108","author":"Gadelha","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0400","article-title":"Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center","volume":"26","author":"Pirchio","year":"2024","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ghir.2024.101608_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1344728","article-title":"Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study","volume":"15","author":"Favero","year":"2024","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ghir.2024.101608_bb0410","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-023-02275-1","article-title":"Real-life data of Pasireotide LAR in acromegaly: a long-term follow-up","author":"Urbani","year":"2024","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ghir.2024.101608_bb0415","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11102-016-0753-y","article-title":"Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly","volume":"20","author":"Tritos","year":"2017","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0420","doi-asserted-by":"crossref","first-page":"E251","DOI":"10.1210\/jc.2010-1742","article-title":"Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study","volume":"96","author":"Marazuela","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0425","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12020-018-1729-7","article-title":"Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies","volume":"63","author":"Leonart","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.ghir.2024.101608_bb0430","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1530\/EJE-08-0205","article-title":"Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials","volume":"159","author":"Jimenez","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0435","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/jc.2009-1239","article-title":"Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study","volume":"95","author":"Buhk","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0440","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1530\/eje.1.02112","article-title":"Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance","volume":"154","author":"Colao","year":"2006","journal-title":"Eur. J. Endocrinol."},{"issue":"Suppl. 1","key":"10.1016\/j.ghir.2024.101608_bb0445","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1530\/EJE-09-0350","article-title":"The German ACROSTUDY: past and present","volume":"161","author":"Buchfelder","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0450","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0455","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0460","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0465","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-9966-32-40","article-title":"J long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes","volume":"32","author":"Bianchi","year":"2013","journal-title":"Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ghir.2024.101608_bb0470","doi-asserted-by":"crossref","first-page":"D17","DOI":"10.1530\/EJE-19-0998","article-title":"Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly","volume":"182","author":"van der Lely","year":"2020","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A pituitary society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0480","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1530\/EJE-19-0124","article-title":"Management of endocrine disease: individualised management of acromegaly","volume":"181","author":"Bollerslev","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0485","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1210\/jcem.86.2.7206","article-title":"Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient","volume":"86","author":"van der Lely","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0490","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1530\/EJE-08-0843","article-title":"Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients","volume":"160","author":"Neggers","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0495","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1210\/jc.2007-1234","article-title":"Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly","volume":"92","author":"Neggers","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0500","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","article-title":"Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly","volume":"99","author":"Neggers","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0505","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-18-0353","article-title":"Efficacy and safety of switching to Pasireotide in acromegaly patients controlled with Pegvisomant and somatostatin analogues: PAPE extension study","volume":"179","author":"Muhammad","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0510","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","article-title":"Strasburger CJ.A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly","volume":"71","author":"Trainer","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0515","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40618-017-0614-1","article-title":"Pegvisomant in acromegaly: an update","volume":"40","author":"Giustina","year":"2017","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ghir.2024.101608_bb0520","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ando.2021.05.004","article-title":"Pegvisomant treatment in acromegaly in clinical practice: final results of the French ACROSTUDY (312 patients)","volume":"82","author":"Barraud","year":"2021","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"10.1016\/j.ghir.2024.101608_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.807054","article-title":"Hyperprolactinemia and hypopituitarism in acromegaly and effect of pituitary surgery: long-term follow-up on 529 patients","volume":"12","author":"Guo","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ghir.2024.101608_bb0530","doi-asserted-by":"crossref","first-page":"14002","DOI":"10.3390\/ijms241814002","article-title":"Prolactin and growth hormone signaling and interlink focused on the Mammosomatotroph paradigm: a comprehensive review of the literature","volume":"24","author":"Araujo-Castro","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ghir.2024.101608_bb0535","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3171\/2018.4.JNS18230","article-title":"Growth hormone and prolactin-staining tumors causing acromegaly: a retrospective review of clinical presentations and surgical outcomes","volume":"131","author":"Rick","year":"2019","journal-title":"J. Neurosurg."},{"issue":"6","key":"10.1016\/j.ghir.2024.101608_bb0540","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/ejendo\/lvae053","article-title":"Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion","volume":"190","author":"Biagetti","year":"2024","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.ghir.2024.101608_bb0545","article-title":"Differences between GH and PRL co-secreting and GH-secreting pituitary adenomas. A series of 604 cases","volume":"202","author":"Araujo-Castro","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0550","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000218323","article-title":"Optimizing medical therapy of acromegaly: beneficial effects of Cabergoline in patients uncontrolled with long-acting release octreotide","volume":"90","author":"Jallad","year":"2009","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ghir.2024.101608_bb0555","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/B:PITU.0000044630.83354.f0","article-title":"Cabergoline therapy of growth hormone & growth hormone\/prolactin secreting pituitarytumors","volume":"7","author":"Freda","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0560","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1530\/eje.0.1390516","article-title":"Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?","volume":"139","author":"Cozzi","year":"1998","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0565","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4158\/EP.13.4.396","article-title":"Coelho, Carlos substantial shrinkage of adenomas Cosecreting growth hormone and prolactin with use of Cabergoline therapy","volume":"13","author":"Vilar","year":"2007","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.ghir.2024.101608_bb0570","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11102-005-5353-1","article-title":"Cabergoline decreases somatotroph adenoma size: a case report","volume":"7","author":"Rickels","year":"2004","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0575","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1210\/jcem.82.2.3648","article-title":"Effect of different dopaminergic agents in the treatment of acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0580","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study in 64 patients","volume":"83","author":"Abs","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0585","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1507\/endocrj.EJ12-0272","article-title":"Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature","volume":"60","author":"Suda","year":"2013","journal-title":"Endocr. J."},{"key":"10.1016\/j.ghir.2024.101608_bb0590","first-page":"278","article-title":"Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature","volume":"66","author":"Kizilgul","year":"2022","journal-title":"Arch. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2024.101608_bb0595","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvae003","article-title":"Efficacy of cabergoline in non-irradiated patients with acromegaly: a multi-Centre cohort study","author":"Urwyler","year":"2024","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ghir.2024.101608_bb0600","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11102-012-0382-z","article-title":"Pegvisomant and cabergoline combination therapy in acromegaly","volume":"16","author":"Bernabeu","year":"2013","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2024.101608_bb0605","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17446651.2016.1222899","article-title":"Somatostatin analogs, cabergoline and pegvisomant: comparing the efficacy of medical treatment for acromegaly","volume":"12","author":"Grasso","year":"2017","journal-title":"Expert. Rev. Endocrinol. Metab."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637424000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637424000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:35:37Z","timestamp":1726360537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637424000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":121,"alternative-id":["S1096637424000388"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2024.101608","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical treatment of acromegaly \u2013 When the tumor size matters: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2024.101608","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101608"}}